Supernus (INDV) Research & Development (2024 - 2026)
Indivior Pharmaceuticals' Research & Development came in at $5 million for Q3 2026, down 84.8% from $33 million a year earlier and down 58.3% from the prior quarter.
Powered by 
Analysis
Supernus (INDV) Research & Development (2024 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Indivior Pharmaceuticals reported Research & Development of $54 million, down 49.5% year-over-year; for FY2025, it was $97 million, down 9.3% from FY2024.
- Research & Development carries a four-year compound annual growth rate of 16.9% (FY2021 to FY2025).
- Going back by year, Research & Development was $107 million in FY2024 (-7.8%), $116 million in FY2023 (+56.8%), $74 million in FY2022 (+42.3%) and $52 million in FY2021.
- The Q3 2026 figure represents the lowest quarterly Research & Development in data going back to Q1 2024.
- Year-over-year, Research & Development has declined for four consecutive quarters, with an average decline of 25.4% over the last seven quarters.
- Business Quant data shows INDV's Research & Development at $12 million (Q2 2026), $16 million (Q1 2026) and $21 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Supernus | 4.28 Bn | 3.38 Bn | 305.00 Mn | 5.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 5.00 Mn |
| Jun 30, 2026 | 12.00 Mn |
| Mar 31, 2026 | 16.00 Mn |
| Dec 31, 2025 | 21.00 Mn |
| Sep 30, 2025 | 33.00 Mn |
| Jun 30, 2025 | 21.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Dec 31, 2024 | 31.00 Mn |
| Sep 30, 2024 | 22.00 Mn |
| Jun 30, 2024 | 26.00 Mn |
| Mar 31, 2024 | 28.00 Mn |
API Access
Supernus Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=INDV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "INDV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=INDV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();